CD34 and breast cancer: Tumour progression was similar in the groups that were co-injected with human breast cancer cells and unprocessed lipoaspirate and those co-injected with human breast cancer cells and purified CD34+ WAT ADSCs, suggesting that most of the tumour progression effects of human WAT are due to the ADSC fraction.